Morepen Laboratories bags ₹825 Cr global deal, forays into high-growth CDMO segment; stock rallies 19.5%
News by Aliceblue News Desk
23 Feb 2026
Introduction
Leading pharmaceutical CDMO secures a ₹825 crore multi-year contract from a global pharma company, expanding manufacturing capabilities and supporting long-term regulated market supply programs.
Also Read: Intellect Design Arena launches AI-powered Academic TeamSpace, signs MoUs with 6 top universities
Share price movement of Morepen Laboratories
On February 23, 2026, Morepen Laboratories Ltd opened at ₹44.36, up 12.82% from its previous close of ₹39.31. The stock reached a high of ₹46.90 (19.33%) and a low of ₹41.60. By 3:23 PM, it traded at ₹44.74, a 13.81% increase, with a market cap of ₹2,451.54 crore.
Morepen Secures ₹825 Crore CDMO Deal
Morepen Laboratories Limited has secured a multi-year CDMO contract worth approximately ₹825 crore from a leading global pharmaceutical company. Supplies are expected to start within 4-5 months.
The contract execution is planned through Q1 of the next financial year, following standard operational and regulatory approvals. This is one of the largest CDMO mandates in Morepen’s history.
Morepen’s internationally accredited facilities, including USFDA, WHO-GMP, and EU approvals, will support the program. The company continues evaluating capacity expansion and technology investments to meet growing global CDMO demand.
Stock performance of Morepen Laboratories for period of 1 week, 6 months, and 1 year
Morepen Laboratories Ltd delivered a 3.26% return over the past week, declined 17.1% in the past 6 months, and fell 24.2% over the past 1 year.
Also Read: GHV Infra shares jump 5% on landing mega rooftop solar contract to serve 14,416 homes
Shareholding pattern of Morepen Laboratories
| Particulars | Dec 2025 | Sep 2025 | Jun 2025 |
| Promoter | 35.70% | 35.70% | 35.70% |
| FII | 1.60% | 1.60% | 1.70% |
| DII | 1.30% | 1.50% | 1.50% |
| Public | 62% | 61% | 61.10% |
About Morepen Laboratories
Morepen Laboratories Ltd (NSE: MOREPENLAB) is an innovation-driven pharmaceutical and healthcare company delivering APIs, generics, medical devices, and wellness products to over 90 countries globally.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
Q: Why is Morepen Laboratories share price rising today?
A: Morepen Laboratories secures ₹825 crore multi-year CDMO contract from a global pharma company, expanding manufacturing footprint and regulated market supplies.
Q: What is Morepen Laboratories’ main business focus?
A: Morepen Laboratories focuses on APIs, branded generics, medical devices, and consumer wellness products supplied to over 90 countries globally.
Q: What are the 52-week high and low of Morepen Laboratories stock?
A: Morepen Laboratories stock has a 52-week high of ₹70.40 and a 52-week low of ₹33.47.
News Author
Aliceblue News Desk
